超过26000例转诊至高通量I期肿瘤单元患者的路径与结局
该回顾性单中心研究纳入2007至2023年转诊至Gustave Roussy药物开发部的26394例患者,评估早期肿瘤试验的转诊至治疗路径。5847例(22%)签署知情同意,4769例(18%)接受至少一剂试验治疗。试验可及性和治疗持续时间因瘤种而异,非小细胞肺癌转诊最多但乳腺、结直肠和胰腺癌治疗率较低。
要点
- 转诊患者中仅18%最终接受试验治疗,瘤种间治疗率差异显著。
- 非小细胞肺癌转诊最多(19%),但乳腺、结直肠和胰腺癌治疗率偏低。
- 距单元距离不影响治疗失败时间,治疗格局向ADC和T细胞衔接器演变。
核心结论
- 这是评估早期肿瘤试验转诊至治疗路径的最大真实世界队列,显示试验可及性和治疗持续时间因瘤种存在差异。
主要发现
- 26394例转诊患者中,13713例(52%)接受会诊评估,5847例(22%)签署知情同意,4769例(18%)接受至少一剂试验治疗,对应5438例次入组。
- 患者来自法国各地,但距单元距离不影响治疗失败时间(TTF)。
- 治疗格局显著演变,抗体药物偶联物和T细胞衔接器出现,传统单克隆抗体减少。
- 非小细胞肺癌是最常转诊瘤种(n=5025,19%),乳腺、结直肠和胰腺癌转诊占比大但治疗率相对较低。
临床怎么用
- 转诊至早期试验的患者中仅少数最终接受治疗,临床转诊时应充分评估瘤种间试验可及性差异。
- 非小细胞肺癌转诊量大,而乳腺、结直肠和胰腺癌治疗率低,提示需关注这些瘤种的未满足需求。
局限性
- 回顾性单中心设计,结果可能受转诊模式和中心实践影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Early-phase oncology trials (EPT) are a mandatory step in anticancer drug development, providing early access to innovative therapies for patients with cancer. The trajectory of patients referred for such selective trials - including treatment access and outcomes across tumour types - remain a challenge. METHODS: This retrospective monocentric study included all patients referred to Gustave Roussy's Drug Development Department between January 1, 2007 and December 31, 2023. Patient characteristics, tumour types, referral patterns, trial inclusion and investigational treatments were collected. Time to treatment failure (TTF) was analysed among treated patients. FINDINGS: Among 26,394 patients referred for EPT, 13,713 (52%) were evaluated in consultation and 5847 signed informed consent for an EPT (22%). Overall, 4769 unique patients received at least one dose of experimental treatment (18%), corresponding to 5438 inclusions. Patients were recruited across France, but distance from the unit did not influence TTF. The therapeutic landscape evolved markedly, with the emergence of antibody-drug conjugates and T-cell engagers and a decline in conventional monoclonal antibodies. Access to EPT varied substantially across tumour types and was not proportional to referral volume. Non-small cell lung cancer was the most referred tumour type (n = 5025, 19%). Breast, colorectal and pancreatic cancers accounted for a large share of referrals but had relatively low treatment rates, highlighting potential unmet medical needs. INTERPRETATION: This study represents the largest real-world cohort evaluating the referral-to-treatment trajectory in EPT. While providing access to therapeutic innovation, disparities in trial access and in treatment duration persist across tumour types.
引用
- Roulleaux Dugage M, Mazza C, Matte P, et al. Access to early-phase oncology trials: Trajectories and outcomes of more than 26,000 patients referred to a high-volume phase I unit. Eur J Cancer. 2026. PMID: 42762559. doi:10.1016/j.ejca.2026.117058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。